Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially blocks α1A receptors in the prostate, leading to smooth muscle relaxation and improved urinary flow in patients with benign prostatic hyperplasia (BPH).
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy for distal ureteral calculi (kidney stones).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily.
* **Ureteric Stones (Off-label):** 0.4 mg orally once daily for up to 4 weeks.
* **Maximum Dose:** 0.8 mg daily (if inadequate response to 0.4 mg after 2–4 weeks; note: increased dose may increase side effects).
## Pediatric Dosing
Tamsulosin is **not indicated** for pediatric use. Pediatric safety and efficacy have not been established. In specialized pediatric urology settings, data on off-label use for voiding dysfunction is limited and based on institutional protocols.
## Dose Adjustments
* **Renal Impairment:** No initial dose adjustment required in mild to moderate impairment. Use caution in severe impairment (CrCl <10 mL/min); data are limited.
* **Hepatic Impairment:** No dose adjustment required for mild to moderate impairment. Do not use in severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Use caution; dose may require reduction or adjustment depending on the strength of the inhibitor.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
* History of orthostatic hypotension.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde ejaculation), orthostatic hypotension, rhinitis, and fatigue.
* **Serious:** Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism (rare), angioedema.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin):** May significantly increase tamsulosin exposure. Avoid or use with extreme caution.
* **Strong CYP2D6 Inhibitors (e.g., paroxetine, fluoxetine):** May increase plasma concentrations of tamsulosin.
* **PDE5 Inhibitors (e.g., sildenafil, tadalafil):** Concurrent use can cause additive blood pressure lowering effects; Initiate at the minimal dose.
## Monitoring
* Monitor blood pressure periodically to assess for orthostatic hypotension.
* Assess symptom improvement via International Prostate Symptom Score (IPSS).
* Assess for cardiovascular symptoms (dizziness/syncope).
* Ophthalmologic evaluation: History of cataract surgery should be noted prior to initiation.
## Clinical Pearls
* **Administration:** Take orally 30 minutes after the same meal each day. Do not crush, chew, or open the capsule.
* **IFIS:** Warn patients scheduled for cataract surgery to inform their ophthalmologist that they are taking or have taken tamsulosin, as it may cause cataract surgical complications.
* **Orthostasis:** Risk is greatest during initial dose titration or after dose increase; suggest rising slowly from sitting/lying positions.
***
*Disclaimer: This information is for educational purposes and reflects general clinical standards. Dosing and clinical protocols may vary by institution and patient-specific factors. Always verify current prescribing information in established pharmacological databases or local clinical guidelines before prescribing or administering medication.*
